Sensor-Enabled Digital Health
TECHNOLOGY
TECHNOLOGY
TECHNOLOGY
INVESTORS
INVESTORS
TECHNOLOGY
RESOURCES
RESOURCES
RESOURCES
TECHNOLOGY
TECHNOLOGY
TECHNOLOGY
TECHNOLOGY
RESOURCES
Describe your image.
Describe your image.
Measuring Therapy Effectiveness Through Sensing and Data Control
Find out how we are transforming the medical industry through continuous sensing, computing and transmission to provide the configurable data that physicians need.
We've started with intraocular pressure (IOP) sensing to help assess glaucoma therapy effectiveness.
Announcements
March 1, 2022
Injectsense Awarded $1.7M NIH Grant for Autonomous IOP Implant
with Micro Battery; Johns Hopkins to Manage Testing
Sept. 1, 2020
Injectsense Receives FDA Breakthrough Device Program Designation
for Continuous IOP Monitoring for Glaucoma
Recent Press
TechCrunch. March 17, 2022 Injectsense Collects $1.7M for Eye Implant Smaller than Grain of Rice
Injectsense Granted $1.7M for IOP Sensor Glaucoma Treatment
An Update on Implantable IOP monitoring
The Ophthalmologist March 12, 2020
Organ to Cloud Technology is Here
Glaucoma Physician Dec. 1, 2019
Sensor for Continuous IOP Monitoring
Injectable Sensor Designed to Keep an Eye on Glaucoma
Technology
Our smart sensor is a self-anchoring platform that interfaces well with media (blood, tissue, other fluids) without interfering with the electronics that support the sensing, computing and transmission of data.
Investors
Injectsense received Series B funding in April of 2019, and is currently engaged in fundraising for Series C.
The Injectsense Difference
Take a look at how the company's Silicon Valley and Twin Cities product teams combine cutting-edge advances in microelectronics with best-in-class medical device development and expertise.
CAUTION - Investigational Device. Limited by Federal law to investigational use.
.